Skip to Content

Iodoquinol Pregnancy and Breastfeeding Warnings

Iodoquinol is also known as: Diquinol, Yodoxin

Iodoquinol Pregnancy Warnings

Iodoquinol use during pregnancy has been described in two patients with acrodermatitis enteropathica. In one patient, iodoquinol was given throughout pregnancy, beginning at dosages of 1.3 grams per day. The dosage was increased to 6.5 grams per day by the end of the pregnancy to control exacerbations of dermatitis. A normal male infant was delivered. Another woman took iodoquinol during the second and third trimester to control cutaneous lesions. She delivered a achondroplastic dwarf which died shortly after birth. The Collaborative Perinatal Project reported 169 exposures during the first trimester and 172 exposures anytime during pregnancy. Birth defects were reported in 10 infants following first trimester exposure (relative risk of 0.88). Congenital hip dislocation accounted for three of these birth defects (relative risk of 6.6). For use anytime during pregnancy, six birth defects were reported (3.6 expected, relative risk of 1.7). Congenital hip dislocation was also reported in three of these infants (relative risk of 6.6). Independent confirmation is needed to confirm association between iodoquinol use during pregnancy and adverse fetal outcome.

Iodoquinol has not been formally assigned to a pregnancy category by the FDA. There are no controlled data in human pregnancy. Iodoquinol is only recommended for use during pregnancy when benefit outweighs risk.

See references

Iodoquinol Breastfeeding Warnings

There are no data on the excretion of iodoquinol into human milk.

See references

References for pregnancy information

  1. Verburg DJ, Burd LI, Hoxtell EO, Merrill LK "Acrodermatitis enteropathica and pregnancy." Obstet Gynecol 44 (1974): 233-7
  2. Vedder JS, Griem S "Acrodermatitis enteropathica (Danbolt-Closs) in five siblings: efficacy of diodoquin in its management." J Pediatr 48 (1956): 212-9

References for breastfeeding information

  1. "Product Information. Yodoxin (iodoquinol)." Glenwood Inc, Tenafly, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.